Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

O’Neill, Suzanne C.; Isaacs, Claudine; Lynce, Filipa; Graham, Deena Mary Atieh; Chao, Calvin; Sheppard, Vanessa B.; Zhou, Yingjun; Liu, Chunfu; Selvam, Nandini; Schwartz, Marc D.; Potosky, Arnold L.

doi:10.1186/s13058-017-0837-2

Table 1 Characteristics of selected cohort and relationship with endocrine initiation and adherence

From: Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

	Initiation			Adherence
	Selected cohort			Selected cohort
	Number	Row %	P	Number	Row %	P
Total	5014	84		4218	61
Recurrence score			<0.0001			0.13
Low (<18)	821	91		745	64
Intermediate (18–30)	621	91		566	63
High (>30)	165	83		137	66
No oncotype	3407	81		2770	60
Year diagnosed			0.06			0.001
2006–2007	1929	85		1639	58
2008–2009	2097	83		1734	63
2010	988	86		845	65
Age at diagnosis, years			0.14			<0.001
24–39	361	81		293	51
40–49	1621	83		1350	60
50–59	2091	85		1784	63
60–63	941	84		791	64
Race-ethnicity			0.10			0.004
NH white	4263	84		3593	62
NH black	188	79		148	49
Hispanic	205	82		168	58
Other/unknown	358	86		309	66
Marital status			0.03			0.002
Not married	1427	82		1177	57
Married	3507	85		2978	63
Missing	80	79		63	63
Prior cancer			0.77			0.24
No	4766	84		4011	61
Yes	248	83		207	61
State			0.04			0.14
CA	1985	83		1642	61
GA	930	83		771	58
KY	483	87		421	62
NY	771	86		662	65
OH	845	85		722	62
Area			0.76			0.15
Rural	254	83		212	57
Urban	4703	84		3959	62
Missing	57	82		47	62
Median household income			0.23			0.03
1 (lowest)	952			802	60
2	921	84		766	61
3	1071	83		892	58
4	999	83		864	62
5 (highest)	1014	86		847	66
Missing	57	84		47	62
Stage			0.001			0.44
I	3035	83		2504	61
II	1979	87		1714	62
Nodal involvement			0.001			0.50
N0	3767	83		3122	61
N1mic	325	87		292	61
N1	922	90		804	63
HER2 status			0.66			0.35
Negative	2283	84		1928	62
Borderline	55	87		48	52
Unknown	2676	84		2242	61
Hormone receptor status			<0.001			0.89
Both ER and PR positive	4299	85		3664	61
Only ER or PR positive	715	77		554	61
Histological grade			0.04			0.17
1–2	3737	85		3175	62
3	1076	82		887	59
Missing	201	78		156	58
One-year comorbidities			0.17			0.08
0	4395	84		3709	62
1 or more	619	82		509	58
Surgery type			0.16			0.45
Breast-conserving surgery	3049	84		2569	62
Mastectomy	1956	85		1642	61
Unknown/missing	9	78		7	71
Endocrine therapy						<0.001
Tamoxifen only	--			1512	58
AIs only	--			1930	65
Tamoxifen and AIs	--			776	58
Adjuvant chemotherapy			<0.001			0.86
No	2585			2084	61
Yes	2429			2134	61

Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least 2 mm in size in at least one of three axillary lymph nodes. NH non-Hispanic, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor, AI aromatase inhibitor

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us